IP Library Granted Patent US 7,585,630
Granted Patent B2
US 7,585,630 · App. 11/454,296 · Granted Sep 8, 2009

Genetic variants in the TCF7L2 gene as diagnostic markers for risk of type 2 diabetes mellitus

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,585,630
App. No.
11/454,296
Granted
Sep 8, 2009
Kind
B2
Abstract

Polymorphisms in the gene TCF7L2 are shown by association analysis to be a susceptibility gene for type II diabetes. Methods of diagnosis of susceptibility to diabetes, of decreased susceptibility to diabetes and protection against diabetes, are described, as are methods of treatment for type II diabetes.

Claims (13)

1. A method of detecting an increased susceptibility to type II diabetes in an individual, comprising analyzing a test sample from the individual for a marker selected from the group consisting of DG10S478, rs12255372, rs7895340, rs11196205, rs7901695, and rs7903146, wherein the presence of a non-0 allele in DG10S478, a T allele in rs12255372; an A allele in rs7895340; a C allele in rs11196205; a C allele in rs7901695; or a T allele in rs7903146 is indicative of an increased susceptibility to type II diabetes.

2. The method of claim 1 , wherein the increased susceptibility is characterized by a relative risk of at least 1.2.

3. The method of claim 2 , wherein the relative risk is at least 1.3.

4. The method of claim 3 , wherein the relative risk is at least 1.4.

5. A method of detecting an increased susceptibility to type II diabetes in an individual, comprising analyzing marker rs7903146 in a test sample from the individual, wherein the presence of T allele in marker rs7903146 is indicative of increased susceptibility to type II diabetes.

6. A method of detecting a decreased susceptibility to type II diabetes in an individual, comprising analyzing a test sample from the individual for a marker selected from the group consisting of DG10S478, rs12255372, rs7895340, rs11196205, rs7901695, and rs7903146, wherein the presence of a 0 allele in DG10S478, a G allele in SNP rs12255372; a G allele in rs7895340; a G allele in rs11196205; a T allele in rs7901695; or a C allele in rs7903146 is indicative of a decreased susceptibility to type II diabetes.

7. The method of claim 6 , wherein the decreased susceptibility is characterized by a relative risk of less than 0.8.

8. The method of claim 7 , wherein the relative risk is less than 0.7.

9. The method of claim 6 , wherein the marker is DG10S478.

10. The method of claim 6 , wherein the marker is rs7903146.

11. A method of detecting an increased susceptibility to type II diabetes in an individual, comprising analyzing a test sample from the individual for marker DG10S478, wherein the presence a non-0 allele in DG10S478 is indicative of an increased susceptibility to type II diabetes.

12. The method of claim 1 , wherein the non-0 allele in DG10S478 is selected from the group consisting of: a −4 allele, a 4 allele, an 8 allele, a 12 allele, a 16 allele, and a 20 allele.

13. The method of claim 11 , wherein the non-0 allele in DG10S478 is selected from the group consisting of: a −4 allele, a 4 allele, an 8 allele, a 12 allele, a 16 allele, and a 20 allele.

Assignments (2)
GRANT OF PATENT SECURITY INTEREST Recorded Nov 12, 2009
From: DECODE GENETICS EHF (IN ICELANDIC: ISLENSK ERFDAGREINING EHF)
To: SAGA INVESTMENTS LLC
Reel/Frame 023510/0243 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2006
From: GRANT, STRUAN F.A.
To: DECODE GENETICS EHF.
Reel/Frame 018168/0920 →